MetaCap

Harmony Biosciences (HRMY) vs Septerna (SEPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Septerna (SEPN) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 51.1% versus a loss of 5.0%. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.84 billion), about 1.0 times the size, while Septerna is growing revenue faster (+4174.5% vs +21.5%). Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -106.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HRMY-5.01%SEPN+51.06%
+111%+41%-29%
Nov 21, 20251 yearNov 20, 2026
HRMY-5.54%SEPN+80.42%
+138%+27%-85%
Oct 21, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HRMY versus SEPN key metrics
MetricHRMYSEPN
Share price$32.59$38.61
Market cap$1.91B$1.84B
1-day change-1.18%-1.51%
YTD return-12.91%+38.49%
1-year return-5.01%+51.06%
5-year return-13.21%—
P/E ratio (TTM)10.79—
Forward P/E5.37—
EPS (TTM)$3.02$-1.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$868.45M$45.95M
Revenue growth (YoY)+21.51%+4174.51%
Net income (latest FY)$158.69M$-48.88M
Gross margin77.16%—
Operating margin24.00%-148.63%
Net margin18.27%-106.37%
52-week high$43.49$53.34
52-week low$25.90$22.78
Distance from 52-week high-25.06%-27.62%
Analyst consensusbuystrong_buy
Avg. price target upside+47.53%+53.38%
Average volume1.01M383.96K
Shares outstanding58.72M47.55M
Employees293134
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SEPN has outperformed HRMY by 56.1 percentage points over the past year.
  • Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
  • Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +21.51%).

About Harmony Biosciences

HRMY stock →

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

About Septerna

SEPN stock →

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees

HRMY vs SEPN FAQ

Which is bigger, Harmony Biosciences or Septerna?

Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.84B for Septerna (SEPN).

Which stock has performed better over the past year, HRMY or SEPN?

SEPN returned +51.06% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.

Are Harmony Biosciences and Septerna in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons